A healthier world through equitable access to advanced lifesaving innovations
Yale School of Public Health – October 8th, 2021
Tevogen Bio to Initiate Clinical Trial of its Investigational T Cell Therapy for COVID-19 at Thomas Jefferson University
Businesswire – September 1st, 2021
Tevogen Bio Revolutionizing Healthcare through an Innovative Public Health Centric Model
Pharma Tech Outlook – August 30th, 2021
Tevogen Bio brings together an experienced team of scientists, industry leaders, public health professionals, and biotech manufacturing experts with the goal of advancing global health.
Our mission is to leverage our proprietary cell and gene therapy platforms to innovate breakthrough and accessible immunotherapeutics for life threatening cancers and viral infections for which limited treatment options are available.
Clinical-Stage Biotechnology Company
New Jersey, USA
Our Innovative Science
Tevogen’s unique allogeneic T cell technology is a major scientific breakthrough
Target Tuning Platform to overcome potential immune escape of SARS-CoV-2 viral variants.
Target Specific T Cell Receptor Engineered CD8+CTL (TCR-Ts) for treatment of Cancers and Viral Infections.
Technology to Bring Targets for Tevogen’s Allogeneic CD8+Cytotoxic T Lymphocytes to Cancer Cells being Marked for Elimination.
We are committed to pioneering lifesaving innovations for viral diseases and cancers for which there is a high unmet need
BioCentriq is New Jersey Innovation Institute’s pioneering cell and gene therapy process development and clinical manufacturing center.
We are dedicated to developing accessible therapeutics for patients impacted by life threatening cancers and viral infections
Message From the CEO
Tevogen was created based on the audacious goal of finding a cure for cancer. This dream inspired us to pursue the development of life-saving therapies for some of the most prevalent illnesses plaguing humanity today.
Our success is rooted in passion and perseverance, and is backed by rigorous science. However, our unrelenting optimism – and belief that learning and adapting means improving – is what propelled us to this moment.
Our corporate culture encourages people to contribute their unique and diverse perspectives, to harness their optimism and creativity, and to be ready to learn and develop solutions together towards a common and greater purpose. We all are different and think differently, it’s okay to fail and make mistakes but learn from the failures – that mindset, respect for each other and irrational optimism is what has made Tevogen a reality.
I am confident in Tevogen’s success, and in our investigational therapies and vaccines. We have brought together accomplished experts in immunotherapy and vaccine development to contribute their knowledge in a practical and efficient way. Tevogen is uniquely positioned to combat several large-scale health problems of today, including COVID-19 and Influenza. I am equally confident in the cancer solutions our oncology portfolio will contribute.
One of our objectives is to ensure that all people, regardless of socioeconomic status, are able to afford our therapies. Affordability of life-saving healthcare is a major challenge of our time. As the founder of Tevogen and its CEO, I am personally delighted to see that what started as an intrepid goal may very well play a critical role in overcoming the biggest public health crisis of our time.
Ryan Saadi, MD, MPH
CEO, Tevogen Bio
© 2021 Tevogen Bio. All Rights Reserved.